COVID-19

 

The Rheumatology Network COVID-19 clinical focus page provides information on the latest COVID-19 news, study and clinical trial findings, and clinical guideline updates for the treatment of COVID-19. We feature expert interviews with leading physicians and investigators, articles, videos, podcasts, and breaking FDA approvals for COVID-19 drugs.

FDA Approves Additional Dose of COVID-19 Vaccine for Immunocompromised Patients

August 16, 2021

The US Food and Drug Administration (FDA) announced it has authorized a third dose of either the Pfizer/BioNTech or Moderna mRNA COVID-19 vaccines for patients with compromised immune systems, such as patients with rheumatic disease.

Patients With Rheumatic Disease Continued Medication, Followed Prophylaxis During Early COVID-19

August 13, 2021

Patients with rheumatic disease reported significant employment status changes, which may imply issues with healthcare access, affordable medication, mental health concerns, and rheumatic disease activity. However, they tended to follow public health advice and continued therapy to mitigate the risk of COVID-19 diagnosis.

Targeted Biologics Did Not Affect Humoral Immunity to First Dose of COVID-19 Vaccine

July 29, 2021

Common immunosuppressant therapies for patients with rheumatic disease, such as methotrexate and targeted biologics, increase risk of serious infection, especially with respiratory pathogens. A recent study investigates the connection between these drugs and functional humoral immunity to the first dose of the COVID-19 vaccine BNT162b2 (Pfizer-BioNTech).

Concierge Medicine: A Rewarding Option for Rheumatologists

July 08, 2021

Irene Kazmers, MD, discusses the heavy administrative burden placed on all practicing physicians in the last decade and why she chose to begin concierge, or membership medicine, a practice model that has "proven to be a tremendous fit for my career at this point in time and made it possible for me to continue as a practicing rheumatologist."

Autoimmune Inflammatory Rheumatic Diseases, High-Dose Corticosteroids Linked to Poor COVID-19 Outcomes

July 07, 2021

Patients with autoimmune inflammatory rheumatic diseases had an increased risk of testing positive for SARS-CoV-2 and worse clinical outcomes of COVID-19, including death, although disease-modifying antirheumatic drugs (DMARDs) did not increase the risk of these outcomes.